REPL Replimune Group2.27+0.32 (+16.4%)
REPL Replimune Group1.82+0.12 (+7.1%)
REPL Replimune Group1.57-3.19 (-67.0%)
Premarket Decliner
REPL Replimune Group4.76-1.15-19.5%
Premarket:1.94-2.82 (-59.2%)
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
Globe NewswireFri, 10-Apr 5:13 PM
After Hours Decliner
After Hours:1.75-3.01 (-63.2%)